GSK (LON:GSK) Shares Cross Above 200 Day Moving Average – Here’s Why

GSK plc (LON:GSK) shares crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of GBX 1,973.11 and traded as high as GBX 2,009. GSK shares last traded at GBX 1,982.96, with a volume of 13,901,154 shares changing hands.

Analyst Ratings Changes

A number of research firms have issued reports on GSK. Berenberg Bank restated a “hold” rating and issued a GBX 2,000 price objective on shares of GSK in a research report on Thursday, March 26th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a GBX 1,900 target price on shares of GSK in a research note on Monday, June 8th. Jefferies Financial Group restated a “buy” rating and set a GBX 2,500 price target on shares of GSK in a report on Thursday, May 28th. Citigroup dropped their price objective on GSK from GBX 2,250 to GBX 2,100 and set a “neutral” rating for the company in a report on Wednesday, May 6th. Finally, Shore Capital Group reiterated a “buy” rating on shares of GSK in a research report on Wednesday, March 25th. Two investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, GSK has a consensus rating of “Hold” and an average price target of GBX 2,034.29.

GSK Trading Up 3.8%

The company has a debt-to-equity ratio of 106.74, a current ratio of 0.79 and a quick ratio of 0.73. The stock’s 50 day moving average is GBX 1,929.70 and its 200-day moving average is GBX 1,974.01. The company has a market capitalization of £80.37 billion, a P/E ratio of 14.10, a P/E/G ratio of 1.24 and a beta of 0.29.

GSK (LON:GSK) last announced its earnings results on Wednesday, April 29th. The company reported GBX 46.50 EPS for the quarter. GSK had a net margin of 17.78% and a return on equity of 35.78%. The firm had revenue of GBX 762.90 billion for the quarter. As a group, equities research analysts anticipate that GSK plc will post 175.980975 earnings per share for the current year.

Insider Buying and Selling at GSK

In related news, insider Vishal Sikka purchased 1,266 shares of the business’s stock in a transaction that occurred on Monday, June 22nd. The shares were bought at an average price of GBX 5,069 per share, for a total transaction of £64,173.54. Also, insider Wendy Becker bought 4,000 shares of the business’s stock in a transaction dated Wednesday, April 29th. The stock was bought at an average cost of GBX 1,963 per share, for a total transaction of £78,520. Insiders acquired a total of 7,630 shares of company stock worth $21,357,859 over the last three months. Company insiders own 0.31% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.